Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 7-8, 2011, Pages 503-506

  Wang, Wen ^a   Wang, Jian ^b   Song, Haihan ^c   Liu, Jie ^d   Song, Bao ^d   Cao, Xuecheng ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b Shanghai Corps Hospital   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHILD; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 79960448449     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0264     Document Type: Article

References (19)

1. Bouqbis L, Izaabel H, Akhayat O, et al. (2003) Association of the CTLA-4 promoter region (-1661G alleles) with type 1 diabetes in the south Moroccan population. Genes Immun 4:132-137. (Pubitemid 38967587)
2. Buonavista N, Balzano C, Pontarotti P, et al. (1992) Molecular linkage of the human CTLA4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics 13:856-861.
3. Chikuma S, Imboden JB, Bluestone JA (2003) Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med 197:129-135. (Pubitemid 36110264)
4. Contardi E, Palmisano GL, Tazzari PL, et al. (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apo-ptosis upon ligand interaction. Int J Cancer 117:538-550. (Pubitemid 41504541)
5. Dorfman HD, Czerniak B (1995) Bone cancers. Cancer 75(1 Suppl):203-210.
6. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-618. (Pubitemid 34752469)
7. Erfani N, Razmkhah M, Talei AR, et al. (2006) Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 165:114-120. (Pubitemid 43343504)
8. Ghaderi A, Yeganeh F, Kalantari T, et al. (2004) Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 86:1-7. (Pubitemid 38918893)
9. Greenwald RJ, Oosterwegel MA, van der Woude D, et al. (2002) CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 32:366-373. (Pubitemid 34173328)
10. Hadinia A, Hossieni SV, Erfani N, et al. (2007) CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 22:2283-2287. (Pubitemid 350145629)
11. Hodi FS, Mihm MC, Soiffer RJ, et al. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100: 4712-4717. (Pubitemid 36457795)
12. Leach DR, Krummel MF, Allison JP (1996) Enhancement of an-titumor immunity by CTLA-4 blockade. Science 271:1734-1736. (Pubitemid 26102823)
13. Ligers A, Teleshova N, Masterman T, et al. (2001) CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2:145-152. (Pubitemid 33674879)
14. Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191-212. (Pubitemid 23115006)
15. Masteller EL, Chuang E, Mullen AC, et al. (2000) Structural analysis of CTLA-4 function in vivo. J Immunol 164:5319-5327. (Pubitemid 30305211)
16. Phan GQ, Yang JC, Sherry RM, et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377. (Pubitemid 36842552)
17. Pure E, Allison JP, Schreiber RD (2005) Breaking down the barriers to cancer immunotherapy. Nat Immunol 6:1207-1210. (Pubitemid 43045629)
18. Sun T, Zhou Y, Yang M, et al. (2008) Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 68:7025-7034.
19. Ueda H, Howson JM, Esposito L, et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511. (Pubitemid 36648570)